These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1066 related articles for article (PubMed ID: 31928355)
1. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment. Wang D; Wang C; Wang L; Chen Y Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355 [TBL] [Abstract][Full Text] [Related]
2. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797 [TBL] [Abstract][Full Text] [Related]
3. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma. Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598 [TBL] [Abstract][Full Text] [Related]
4. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209 [TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. Dréan A; Goldwirt L; Verreault M; Canney M; Schmitt C; Guehennec J; Delattre JY; Carpentier A; Idbaih A Expert Rev Neurother; 2016 Nov; 16(11):1285-1300. PubMed ID: 27310463 [TBL] [Abstract][Full Text] [Related]
6. The influence of the blood-brain barrier in the treatment of brain tumours. Rathi S; Griffith JI; Zhang W; Zhang W; Oh JH; Talele S; Sarkaria JN; Elmquist WF J Intern Med; 2022 Jul; 292(1):3-30. PubMed ID: 35040235 [TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Drug Resistance in Glioblastoma. Dymova MA; Kuligina EV; Richter VA Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203727 [TBL] [Abstract][Full Text] [Related]
8. Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases. Chen L; Zeng D; Xu N; Li C; Zhang W; Zhu X; Gao Y; Chen PR; Lin J ACS Appl Mater Interfaces; 2019 Nov; 11(45):41889-41897. PubMed ID: 31615203 [TBL] [Abstract][Full Text] [Related]
9. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers. Farshbaf M; Mojarad-Jabali S; Hemmati S; Khosroushahi AY; Motasadizadeh H; Zarebkohan A; Valizadeh H J Control Release; 2022 May; 345():371-384. PubMed ID: 35301054 [TBL] [Abstract][Full Text] [Related]
10. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands. Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462 [TBL] [Abstract][Full Text] [Related]
11. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241 [TBL] [Abstract][Full Text] [Related]
12. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials. Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126 [TBL] [Abstract][Full Text] [Related]
13. Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective. Wu SK; Tsai CL; Hynynen K Handb Exp Pharmacol; 2022; 273():351-364. PubMed ID: 33454856 [TBL] [Abstract][Full Text] [Related]
14. Nanoparticles: Novel vehicles in treatment of Glioblastoma. Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272 [TBL] [Abstract][Full Text] [Related]
15. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. Ganipineni LP; Danhier F; Préat V J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958 [TBL] [Abstract][Full Text] [Related]
17. Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB. Chen C; Duan Z; Yuan Y; Li R; Pang L; Liang J; Xu X; Wang J ACS Appl Mater Interfaces; 2017 Feb; 9(7):5864-5873. PubMed ID: 28128553 [TBL] [Abstract][Full Text] [Related]
18. WINDOW consortium: A path towards increased therapy efficacy against glioblastoma. Abdul KU; Houweling M; Svensson F; Narayan RS; Cornelissen FMG; Küçükosmanoglu A; Metzakopian E; Watts C; Bailey D; Wurdinger T; Westerman BA Drug Resist Updat; 2018 Sep; 40():17-24. PubMed ID: 30439622 [TBL] [Abstract][Full Text] [Related]
19. Novel delivery methods bypassing the blood-brain and blood-tumor barriers. Hendricks BK; Cohen-Gadol AA; Miller JC Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219 [TBL] [Abstract][Full Text] [Related]
20. Current Development of Glioblastoma Therapeutic Agents. Wang Z; Peet NP; Zhang P; Jiang Y; Rong L Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]